tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CRVO Stock Latest News

CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
RatingsCervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
8h ago
CRVO
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
PremiumThe Fly
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
8h ago
CRVO
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
PremiumRatings
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
10h ago
CRVO
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
PremiumCompany Announcements
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
3d ago
CRVO
CervoMed announces presentations at AP/PD 2026 scientific conference
PremiumThe Fly
CervoMed announces presentations at AP/PD 2026 scientific conference
5d ago
CRVO
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
PremiumMarket NewsBuy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
12d ago
CRVO
TCRX
CervoMed Advances Neflamapimod With Phase 1 Completion
Premium
Company Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
13d ago
8K
CRVO
CervoMed completes Phase 1 volunteer study for neflamapimod
Premium
The Fly
CervoMed completes Phase 1 volunteer study for neflamapimod
13d ago
CRVO
CervoMed’s Neflamapimod Added to U.K. ALS Platform
PremiumCompany Announcements
CervoMed’s Neflamapimod Added to U.K. ALS Platform
27d ago
8K
CRVO
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
PremiumRatings
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
27d ago
CRVO
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
PremiumThe Fly
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
27d ago
CRVO
CervoMed Releases Updated Investor Presentation and Business Overview
PremiumCompany Announcements
CervoMed Releases Updated Investor Presentation and Business Overview
2M ago
8K
CRVO
CervoMed initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyCervoMed initiated with an Overweight at Cantor Fitzgerald
3M ago
CRVO
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
Premium
Ratings
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
3M ago
CRVO
CervoMed’s Promising Phase 2b Trial Results for DLB
Premium
Company Announcements
CervoMed’s Promising Phase 2b Trial Results for DLB
3M ago
8K
CRVO
CervoMed’s neflamapimod shows efficacy in slowing dementia
PremiumThe Fly
CervoMed’s neflamapimod shows efficacy in slowing dementia
3M ago
CRVO
Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
PremiumRatings
Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
3M ago
CRVO
CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
PremiumThe Fly
CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
4M ago
CRVO
CervoMed’s Promising First-Mover Advantage in Dementia with Lewy Bodies Treatment: Buy Rating Reaffirmed
PremiumRatings
CervoMed’s Promising First-Mover Advantage in Dementia with Lewy Bodies Treatment: Buy Rating Reaffirmed
4M ago
CRVO
CervoMed Reports Q3 2025 Financial Results and Progress
PremiumCompany AnnouncementsCervoMed Reports Q3 2025 Financial Results and Progress
4M ago
CRVO
CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating
Premium
Ratings
CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating
4M ago
CRVO
CervoMed price target lowered to $19 from $20 at Roth Capital
Premium
The Fly
CervoMed price target lowered to $19 from $20 at Roth Capital
4M ago
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >